The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030

The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.

Adaptimmune
Agios Pharmaceuticals
Agenus
Athenex
Eisai
Eli Lilly
GlaxoSmithKline
Karyopharm Therapeutics
Mirati Therapeutics
PharmaMar
For additional details, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html

Leave a Reply

Your email address will not be published. Required fields are marked *

The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030

Recent advances in molecular biology have enabled researchers to develop a better understanding of the rare soft tissue sarcomas; as a result, a number of viable biological targets have been identified and are being investigated for therapeutic relevance

Roots Analysis has announced the addition of “Soft Tissue Sarcoma Market: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report to its list of offerings.

Soft tissue sarcoma is a rare form of cancer that usually originates in soft / connective tissues and most commonly affects the abdomen, arms, head, legs, neck and trunk of the individual. It is worth noting that, till date, many types (50+) of soft tissue sarcoma have been identified. However, since these tumors possess a large set of entities, their diagnosis is often difficult. At present, there is a growing need for effective and targeted treatment options.

To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html.

Leave a Reply

Your email address will not be published. Required fields are marked *